Pipeline

February 26, 2018
Company Drug/Device Medical Condition Status
Arch Biopartners AB569 antibiotic-resistant bacterial infections in the lungs of cystic fibrosis and chronic obstructive pulmonary disease Phase I trials initiated in the U.S.
Xencor XmAb18087 neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST) Phase I trials initiated
PQ Bypass DETOUR Long (>15 cm) superficial femoral artery (SFA) blockages Phase I trials initiated enrolling 292 subjects in the U.S. and Europe
Therachon TA-46 achondroplasia Phase I trials initiated enrolling 70 subjects in the Netherlands
OncoPep PVX-4106 metastatic triple negative breast cancer (TNBC) who are human leukocyte antigen A2 positive (HLA-A2+) Phase Ib trials initiated
Bonti EB-001 scar reduction Phase II trials initiated
AbbVie JAK1-selective inhibitor adult patients with moderate to severe atopic dermatitis Phase II trials initiated
IRX Therapeutics IRX-2 squamous cervical intraepithelial neoplasia 3 or vulvar intraepithelial neoplasia 3 Phase II trials initiated
Glenmark Pharmaceuticals GBR 830 moderate to severe atopic dermatitis Phase IIa trials initiated enrolling 64 subjects
Centrexion Therapeutics CNTX-4975 Chronic moderate to severe knee osteoarthritis Phase III trials initiated enrolling 325 subjects
AstraZeneca IMFINZI® unresectable Stage III non-small cell lung cancer following CRT Phase III trials initiated
Celgene OTEZLA \(apremilast) active Behçet’s Disease Phase III RELIEF trials initiated
Vertex Pharmaceuticals Incorporated VX-659 cystic fibrosis Phase III trials initiated enrolling 360 patients
Eli Lilly Taltz (ixekizumab) moderate to severe genital psoriasis Phase IIIb trials initiated enrolling 149 subjects
Evofem Biosciences Amphora urogenital chlamydia infection in women Fast Track designation granted by the FDA
Novartis Cosentyx (secukinumab) moderate to severe plaque psoriasis FDA approved label update

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here